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ABSTRACT
We have developed and validated a novel site-
specific mutagenesis assay, termed SSMA-MS,
which incorporates MALDI-ToF mass spectrometry
(MALDI-MS) analysis as a means of determining
the mutations induced by a single DNA adduct. The
assay involves ligating an adducted deoxyoligonu-
cleotide into supF containing pSP189 plasmid. The
plasmid is transfected into human Ad293 kidney
cells allowing replication and therefore repair or a
mutagenic event to occur. Escherichia coli indicator
bacteria are transformed with recovered plasmid
and plasmids containing the insert are identified
colormetrically, as they behave as frameshift muta-
tions. The plasmid is then amplified and digested
using a restriction cocktail of Mbo11 and Mnl1 to
yield 12 bp deoxyoligonucleotides, which are char-
acterized by MALDI-MS. MALDI-MS takes advantage
of the difference in molecular weight between bases
to identify any induced mutations. This analysis
method therefore provides qualitative and quantita-
tive information regarding the type and frequency of
mutations induced. This assay was developed and
validated using an O
6-methyl-20-deoxyguanosine
adduct, which induced the expected GC!AT sub-
stitutions, when replicated in human or bacterial
cells. This approach can be applied to the study of
any DNA adduct in any biologically relevant gene
sequence (e.g. p53) in human cells and would be
particularly amenable to high-throughput analysis.
INTRODUCTION
Many structural and biological features inﬂuence the muta-
genic potential of a genotoxic chemical. The chemical struc-
ture of the DNA adduct including stereochemistry, can have
a major affect on repair and mutagenesis (1). Furthermore,
the DNA sequence surrounding an adduct can have a
profound inﬂuence, probably due in part, to effects on the
3-dimensional structure of the adduct or interference with
base pairing and the resulting DNA distortions. For example,
the bulky C8-deoxyguanosine adduct of 2-amino-1-methyl-
6-phenylimidazo[4,5-b]pyridine (PhIP) has been shown to
cause signiﬁcant bending of the double helix (2). In contrast,
methylation of the N7 position of deoxyguanosine has almost
no effect on DNA conformation whilst alkylation of the O
6
group of deoxyguanosine has severe structural consequences
due to alterations in hydrogen bonding (3). Changes in
sequence context, even at bases distant to the site of adduc-
tion can have effects on the biological outcomes (4,5).
Consequently, the mutagenicity of a particular adduct may
often be dependent on the gene it is present in. It is therefore
important to be able to study the repair and mutagenicity of
individual structurally deﬁned adducts in numerous sequence
contexts, preferably in genes relevant to human cancer.
Many methods have been developed to investigate mutage-
nesis using synthetic oligonucleotides containing single DNA
adducts and these can be grouped according to whether rep-
lication occurs in bacterial or mammalian cells and whether
the adduct is situated in double or single stranded DNA.
Numerous assays have been based on the M13 viral genomes
containing a single DNA adduct, which are then transfected
into Escherichia coli. The resulting mutations can be detec-
ted with a variety of methods, such as DNA sequencing
(6), hybridization (7) or REAP analysis (8–10). Although
methods like this increase our understanding of the muta-
genicity of DNA lesions in E.coli in single stranded DNA,
they do not pertain to mammalian systems and in particular
human cells.
In order to investigate the mutagenicity of DNA adducts
in mammalian systems a variety of methods have been
developed. One such assay, using simian kidney (COS-7)
cells has been used to investigate the mutagenic properties
of a wide range of lesions (11). This method uses a single
stranded shuttle vector which has the DNA adduct of choice
(in this case dG-N
2-tamoxifen) inserted. It was shown that
these lesions induced primarily GC!TA transversions in
this system, as expected for a bulky type DNA adduct and
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Other types of approaches using DNA duplexes (14) and
shuttle vector plasmids (15,16) have allowed the investigation
of how various DNA repair enzymes cope with DNA lesions,
speciﬁcally those derived from 2-acetylaminoﬂuorene. For
example, a recent report characterized the involvement of
DnaE in mutagenesis; due to its lack of proof-reading
functions, low processivity and relaxed active site, it can
bypass lesions which would generally block high ﬁdelity
polymerases (17). A novel plasmid based method for homo-
logous recombination (18) has also been recently added to
the growing array of mutagenesis assays.
The supF assay (19,20) is another shuttle vector based
forward mutation assay which has been widely used to inves-
tigate mutagenesis from a variety of carcinogenic compounds
(4,5,12,13,21–27), mainly due to the beneﬁt of its applicabil-
ity to human cells. This assay is, however, not site speciﬁc
as it involves treating a double stranded plasmid with a reac-
tive compound to generate an array of adducts at a variety of
positions throughout the plasmid. The assay does detect 97%
of possible base substitutions within the 85 bp supF gene (22)
as well as deletions and insertions and because the plasmid is
treated in vitro, aliquots of the treated DNA can be analysed
for adduct quantiﬁcation in parallel to the mutation assay.
The supF gene is however, a non-essential sequence, so
any mutations which are induced would not affect the cell
survival or other pathways of carcinogenesis. The use of
CpG methylated plasmid DNA means that the pattern of
mutations in the supF gene can be transformed to a possible
p53 mutation spectrum using an algorithm described by
Lewis and Parry (28). Methods such as the standard supF
assay are therefore extremely useful for looking at the
range of mutations which can be induced by a particular
chemical and predicting mutations in other relevant genes.
They cannot, however, distinguish the mutational potential
of the different DNA adducts formed. To do this a single
adducted deoxyoligonucleotide would need to be inserted
at a deﬁned place in the plasmid. In addition, the supF
assay relies on DNA sequencing of recovered plasmid, either
using labeled PAGE electrophoresis or automated method-
ologies and these systems are both time consuming and
expensive.
In order to address these limitations we describe in this
manuscript a novel site-speciﬁc mutation assay which is an
adaptation of the supF assay routinely used in our laboratory
and beneﬁts from the use of MALDI-ToF mass spectrometry
(MALDI-MS) for the characterization of mutations. Synthetic
deoxyoligonucleotides containing an O
6-methyl-deoxyguano-
sine (O
6-MedG) were inserted into the supF gene of the
pSP189 plasmid (19,20). When the plasmid is transfected
into and recovered from, human cells the presence of the syn-
thetic insert acts as a frameshift mutation, thus inactivating
the supF gene, resulting in the production of white mutant
colonies (Figure 1). PCR followed by digestion with
Mbo11/Mnl1 yields small (12 base) double stranded deoxy-
oligonucleotides which were then analysed by MALDI-MS
(Figure 2). The increased throughput and reduced cost of
using mass spectrometry for analysis will allow the
rapid screening of the mutations induced by multiple DNA
lesions produced by a single compound in different sequence
contexts. This technique can ultimately provide insight into
the initiation processes of carcinogenesis.
MATERIALS AND METHODS
Materials
All chemicals were from Sigma (Poole, Dorset, UK) unless
otherwise stated.
Shuttle vector plasmid, bacterial strain and cell lines
The plasmid pSP189 containing the supF gene (19,20) and
E.coli strain MBM7070 were gifts from M. Seidman, National
Institute of Aging, NIH, Baltimore, MD, USA. Human
embryonic adenovirus-transformed kidney cells (Ad293) were
cultured from cells previously provided by Dr A. Dipple,
National Cancer Institute, Frederick, MD, USA. Ad293
cells were grown in DMEM, supplemented with 10% fetal
calf serum at 37 C, in 5% CO2 in air.
Deoxyoligonucleotides
Deoxyoligonucleotide inserts (INS1A and INS1B, where
G is the proposed site of adduction for adduct contain-
ing deoxyoligonucleotides), mass spectrometry standards
(STANDARD1 through to STANDARD8) and PCR primers
ALMS3a and 4 were synthesized by Biomers.net GmbH
(Ulm, Germany). The O
6-MedG containing deoxyoligonu-
cleotide was synthesized by Sigma-Genosys (Haverhill,
Suffolk). INS1A: CTTCCTCGCTCTTC; INS1B: GAAGA-
GUGAGGAAG; STANDARD1: TCCTCACTCTTC; STAN-
DARD2:AAGAGTGAGGAA; STANDARD3:TCCTCGCT-
CTTC; STANDARD4:AAGAGCGAGGAA; STANDARD-
5:TCCTCCCTCTTC; STANDARD6: AAGAGGGAGGAA;
STANDARD7: TCCTCTCTCTTC; STANDARD8: AAGA-
GAGAGGAA; ALMS3A: GAA CCT TCG AAG TCG
ATG ACG GCA GAT TTA GAG TCT GCT CCC TTT
GGC CG, ALMS4: CTC GAG CTG TGG TGG GGT TCC
CGA GCT.
Two versions of the INS1A insert were synthesized; one
with a deoxyguanosine and one with an O
6-MedG deoxy-
oligonucleotide. INS1B contains a uracil which will be
situated opposite the variable G site of INS1A during vector
construction and transfection, to encourage translesion
synthesis (29) rather than damage avoidance and replication
of the complementary strand.
Prior to use, all deoxyoligonucleotides were desalted
by precipitation using 5 ml 3 M sodium acetate and 100 ml
ethanol, per optical density unit (ODU). The deoxyoligonu-
cleotides were then brieﬂy vortexed and stored at  20 C
overnight. The desalted deoxyoligonucleotides were recov-
ered by centrifuging for 5 min at 14000 r.p.m. at 4 C and
removing the supernatant. Pellets were re-suspended twice
more in 70% ethanol (800 ml), centrifuged (5 min at 14000
r.p.m. at 4 C) and the supernatant removed. Finally the
pellets were washed with 100% ethanol (100 ml per ODU)
and centrifuged, as before, then the supernatant was removed
and traces of solvent were removed by vacuum centrifugation
of the deoxyoligonucleotide pellet (Savant Industries Inc.,
Farmingdale, NY, USA). The desalted deoxyoligonucleotides
were dissolved in 100 ml sterile water and the concentration
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inserts (INS1A/B) were diluted to  2–10 nmol/ml and the
PCR primers (ALMS3A/ALMS4) to 50 pmol/ml with tissue
culture grade water and stored at  20 C prior to use. Mass
spectrometry standards were stored dry at  20 C until
required.
Digestion of pSP189 plasmid
To enable insertion of the deoxyoligonucleotides, the pSP189
Plasmid (10 mg, 3 pmol) was digested with Bsrb1 restriction
enzyme [40 U; New England Biolabs (UK) Ltd, Hitchin, UK]
in NEBuffer 2 [50 mM sodium chloride, 10 mM Tris–HCl,
Figure 1. Outline of MALDI-MS site-selective mutation assay (SSMA-MS).
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supplemented with 100 mg/ml BSA, in a total volume of
50 ml, for 2 h at 37 C. Bsrb1 cleaves at the GAGCGG restric-
tion site producing blunt ended linear plasmid as shown
in Figure 2. The restriction enzyme is not inactivated or
removed post digestion to reduce re-annealing of the
plasmid. The restriction site will be removed upon ligation
of the insert.
Annealing, phosphorylation and ligation of
deoxyoligonucleotide insert
Complimentary deoxyoligonucleotides (INS1A/B; 20 nmol
of each) were annealed to form INS1 by heating to 98 C
and slowly cooling to 30 C over 2 h. Double stranded deoxy-
oligonucleotides were then phosphorylated using polynu-
cleotide kinase (USB, Cleveland, OH, USA; 5 ml, 150 U)
in a total volume of 50 ml buffer [50 mM Tris–HCl
(pH 7.6), 10 mM MgCl2, 10 mM 2-mercaptoethanol and
2 mM ATP] at 37 C for 2 h. Phosphorylated deoxyoligonu-
cleotide inserts (2 nmol) were ligated into digested pSP189
plasmid (1 mg) using Bioline Quickstick DNA ligase (Bioline,
London, UK) in 3.6 mM Tris–HCl, pH 7.4, 36 mM NaCl,
360 mM DTT, 36 mM EDTA and 18% glycerol in a total
volume of 14 ml, at room temperature for 20 min.
Transfection
Ad293 human kidney cells were transfected with the
modiﬁed pSP189 plasmid as previously described (12,22).
In short, sub-conﬂuent cells were transfected with plasmid
containing the INS1 insert (10 mg per 9 cm culture plate)
using Fugene-6 transfection reagent (15 ml, Roche, Lewes,
East Sussex, UK). The plasmid was recovered after a period
of 48 h using plasmid puriﬁcation kits (Qiagen, Crawley,
UK) and then digested with Dpn1 restriction enzyme
Figure 2. Flow diagram of methods for MALDI-MS site-selective mutation assay (SSMA-MS).
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any plasmid DNA that did not undergo replication in the
human cells.
Transformation of electrocompetent MBM7070 E.coli
Electrocompetent MBM7070 E.coli were transformed with
aliquots of recovered plasmid by electroporation, using
Gene Pulser apparatus (2.5 KV, 200 W,2 5mF) (BioRad,
Hercules, CA, USA). Transformants were plated onto LB
agar plates containing ampicillin (100 mg/ml), which selects
for those cells containing the plasmid, 5-bromo-4-chloro-
3-indolyl-b-D-galactose (X-gal) (75 mg/ml) and isopropyl-
b-D-thiogalactoside (IPTG) (25 mg/ml). White mutant
colonies result from INS1 being successfully ligated into
the supF gene of pSP189 plasmid. All white colonies were
picked, re-streaked on fresh LB agar plates containing ampi-
cillin (100 mg/ml), X-gal (75 mg/ml) and IPTG (25 mg/ml)
and stored at 4 C prior to use. Blue non-mutant (wild-type)
colonies arose from the transformation of plasmid which
did not contain the insert and could therefore be excluded
from subsequent analysis.
PCR
For each white colony an 89 bp region of the plasmid was
ampliﬁed directly by PCR as follows: PCR HotMasterMix
(20 ml, 2.5·, Eppendorf, Hamburg, Germany), tissue culture
grade water (27 ml), ALMS3A (1 ml, 50 pmol), ALMS4
(1 ml, 50 pmol) and 1 ml MBM7070 E.coli (colony picked
and diluted into 20 ml tissue culture grade water) was
introduced into a 200 ml thin walled PCR tube and subjected
to the following optimized PCR program using a Dyad ther-
mal cycler (MJ Research, Inc.,Waltham, MA, USA): 95 C for
5 min followed by 30 cycles of 95 C for 30 s, 60 C for 30 s,
72 C for 60 s, ﬁnal extension at 72 C for 5 min, then cooled
to 4 C. Samples were then stored at  4 C until required.
Digestion of PCR products to yield
deoxyoligonucleotides for MALDI-MS analysis
The 89 bp PCR products (50 ml) were digested with Mnl1 and
Mbo11 restriction enzymes (New England Biolabs (UK) Ltd,
Hitchin, UK) (40 U each) in NEBuffer 2 (10 mM Tris–HCl,
50 mM NaCl, 10 mM MgCl, 1 mM DTT, pH 7.9 at 25 C)
supplemented with 100 mg/ml BSA in a total volume of
80 ml for 2 or 8 h at 37 C. The restriction enzymes were
heat inactivated at 65 C for 20 min.
Sample preparation for MALDI-MS
Digested PCR products were desalted and concentrated using
Amicon Microcon (Millipore, Watford, UK) 3000 Da cut off
spin columns, by centrifugation for 30 min. The samples were
further washed with deionised water (18.2 MW) and each
concentrated sample was re-suspended in 10 ml of MALDI
matrix. The MALDI matrix was composed of ammonium
citrate dibasic [0.2 M in 300 ml of acetonitrile and deionised
water (50:50)] and to this was added 0.2 M of nicotinic acid
and 80 mM of anthranilic acid, along with 650 ml of aceto-
nitrile and 150 ml of deionised water. To each sample,
12 ml Dowex 80 W X200 beads (activated with ammonia)
were added and left to exchange cationic adducts (30 min).
Mass spectrometry
All analyses were performed on a Waters QToF Ultima Glo-
bal instrument (Waters, Manchester, UK) in MALDI mode.
Calibration of the instrument was carried out using a number
of oligonucleotide standards (STANDARD1-8) that covered
the m/z range of interest (m/z 3000–7000 was typically
chosen for analysis). Each digested deoxyoligonucleotide
sample (1 ml) was spotted on to a target in quadruplicate
and the resultant spectra combined. The data was smoothed
using a mean method and the monoisotopic (for standards)
or average molecular weight (for samples) was determined
from the molecular ion.
Sequencing
To independently conﬁrm and validate the MS analyses, plas-
mid samples were also analyzed by standard DNA sequenc-
ing methodologies. In this case, plasmid DNA from white
mutant colonies containing the insert underwent Templiphi
ampliﬁcation and sequencing was carried out using the
primer 50-GGCGACACGGAAATGTTGAA-30 (Biomers.net
GmbH, Ulm, Germany). Sequencing was performed using
an Applied Biosystems Model 377 DNA sequencer using
BigDye sequencing chemistries (Complement Genomics
Ltd, Sunderland, UK).
Mutation classification
PCR products were digested as described and run on a gel
(4% agarose, 30 min at 100–150 V or 20% PAGE, 250 V,
O/N) to check for the presence of the digested insert.
The deoxyoligonucleotide was then classiﬁed as a base sub-
stitution based on the mass of the deoxyoligonucleotide
using MALDI-MS. Deletions were classiﬁed due to a reduced
sized product on the gel and the lack of the appropriate m/z
value in the MALDI-MS spectrum. All mutations were
corroborated with the DNA sequence. Samples which did
not yield full size PCR products were excluded from the
analysis, as these will have deleted regions of the supF
gene, which is probably due to incorrect ligation. Mutations
in the Bsrb1 restriction site will result in PCR products of
approximately the correct size, but upon digestion with
Mbo11 and Mnl1 no product will be produced.
RESULTS
Optimisation of molecular methodology
To develop and validate this assay the deoxyoligonucleotide
sequence INS1A CTTCCTCGCTCTTC was incorporated
into the plasmid. This sequence was designed to contain a
single guanine, enabling the future study of deoxyoligonu-
cleotide adducts prepared by direct reaction of chemicals
that preferentially bind to guanine residues in cases where
phosphoramidite chemistry is not appropriate. We have previ-
ously investigated the mutagenicity of many such compounds
using the standard supF assay, including tamoxifen, benzo(a)-
pyrene diol epoxide, hydroquinone and para-benzoquinone,
which preferentially form bulky adducts with deoxyguano-
sine (12,13,22,24–26). For the purpose of assay development,
in order to avoid a lengthy synthesis and puriﬁcation,
the same deoxyoligonucleotide (INS1A) containing the
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6-MedG adduct was purchased.
Prior to use the presence of the O
6-MedG adduct was
conﬁrmed by MALDI-MS [protonated molecular ion of m/z
4130 for the adducted deoxyoligonucleotide compared to
m/z 4115 for unmodiﬁed INS1A (Figure 3)].
Both standard inserts (INS1A containing unmodiﬁed dG)
and inserts containing the O
6-MedG adduct were annealed
with their complimentary deoxyoligonucleotide (INS1B)
and ligated into the supF gene of the pSP189 plasmid at
the Bsrb1 restriction site. Puriﬁcation of the fully ligated
plasmid was not necessary at this stage, as the assay later
selects for plasmids containing the insert: it can distinguish
correctly ligated plasmid from all other products including
the parent plasmid, when the replicated plasmid is screened
in E.coli. The plasmids were then used to transform
MBM7070 E.coli, which was plated on selective media;
containing ampicillin to select for the presence of the plasmid
and X-gal and IPTG to identify plasmids containing the
deoxyoligonucleotide insert. The efﬁciency of ligation was
in the range of 43–73%, i.e. between 43 and 73 white mutant
colonies were seen per  100 total (blue and white) colonies.
Any mutations caused by incorrect ligation at this stage
will result in a lack of observable digest product in later
steps. White colonies containing the insert were picked and
re-streaked and plasmid DNA was ampliﬁed and sequenced
to verify the presence of the deoxyoligonucleotide insert.
Figure 4 illustrates an example of a sequencing electrophero-
gram from a plasmid containing the ligated deoxyoligonu-
cleotide insert, in this case as the dG control version of
INS1. Figure 5 illustrates an electropherogram from a plas-
mid which contained the deoxyoligonucleotide INS1 insert
with an O
6-MedG adduct present, which has been converted
to an adenine base during replication.
Various restriction enzymes were assessed for their ability
to accurately and efﬁciently digest out the inserted deoxy-
oligonucleotides for MS sequence analysis. These included
Bpm1 (30), which caused problems due to the fact that it is
a type II restriction enzyme and appeared to remain bound
to the digested fragments, adversely affecting recovery and
subsequent MS detection. This issue was also recognized
by Abdi et al. (31), who described a system using Hph1.
Further developments led to the testing of Alu1, Msp1,
Mbo11 and Mnl1 enzymes, with Mbo11 and Mnl1 together
producing the cleanest and most reproducible digestion.
The restriction site topography of the Mbo11 and Mnl1
cocktail results in deoxyoligonucleotides of the same size,
whether or not the original insert was ligated in a forward
or backward orientation at the blunt ended Bsrb1 restriction
Figure 3. Mass spectrum of the INS1A deoxyoligonucleotide with the O
6-MedG adduct in situ.
Figure 4. Sequencing electropherogram of pSP189 plasmid containing control INS1 deoxyoligonucleotide insert showing a GC!GC non mutation.
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deoxyoligonucleotide fragments. When the deoxyoligonu-
cleotide is ligated in the forward orientation, there are two
fragments from the digestion, whereas if the deoxyoligonu-
cleotide insert is ligated in the reverse orientation, in addition
to the same two digestion products, two smaller fragments,
a 9 and 10mer, were also generated (Figure 6). The presence
of these extra two deoxyoligonucleotides will enable deter-
mination of whether the DNA lesion was originally present
on the leading or lagging strand and identiﬁcation of any
strand dependent differences in the mutagenic potential of
the adduct under investigation.
The assay was further validated by ligating synthetic
inserts (INS1) corresponding to all of the possible mutational
outcomes (i.e. G, C, A or T) into the pSP189 plasmid and
transforming MBM7070 E.coli with the plasmids. Resultant
white colonies were picked and ampliﬁed prior to sequen-
cing using the Templiphi method. It was found that the
deoxyoligonucleotides ligated correctly for all of the inserts
and correctly matching sequences were detected for all possi-
ble outcomes. For example, when a T was in place of the
dG, 100% of the plasmids sequenced contained a T in this
position (data not shown).
Optimization of mass spectrometry using
deoxyoligonucleotide standards
The assay was initially developed with a view to using
electrospray ionization mass spectrometry (ESI-MS) analysis
for mutation identiﬁcation, since the clean up and concen-
tration steps could be coupled to the mass spectro-
meter directly using LC-MS methodologies. However, this
approach proved difﬁcult and the inability to detect the
expected molecular ions by mass spectrometry using ESI
may have been due to high salt concentrations in the sample,
therefore various methods were attempted to desalt the
Figure 5. Sequencing electropherogram of pSP189 plasmid containing INS1 O
6-MedG deoxyoligonucleotide insert showing a GC!AT transition.
Figure 6. Digestion of supF gene containing insert.
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dures, HPLC mobile phases, gradients and ﬂow rates were
all attempted but no signiﬁcant improvement in ESI-MS
analysis was observed. It was decided to pursue MALDI
techniques in light of this to try and simplify sample
preparation and analysis.
Deoxyoligonucleotide standards for all of the possible
deoxyoligonucleotides were synthesized, i.e. INS1A contain-
ing either wild type G or possible mutant bases A, C or T.
These were annealed with their appropriate complementary
strands and analysed using MALDI-MS. The source condi-
tions should denature the deoxyoligonucleotides, although
all standards were also analyzed as pure single stranded
deoxyoligonucleotides to conﬁrm the results were com-
parable. Table 1 illustrates the observed masses and the
equivalent calculated masses for all possible top and bottom
strands. The difference in mass between observed and
expected was acceptably low and in the range of 19–
52 p.p.m. (i.e. 0.0019–0.0052%).
Detection of deoxyoligonucleotides recovered from
E.coli using mass spectrometry
A random selection of bacterial colonies that were shown by
conventional sequencing to contain the desired insert were
picked and ampliﬁed as above and PCR products were
digested with Mbo11 and Mnl1 restriction enzymes. The
digested deoxyoligonucleotides were desalted using 3 kDa
cut off spin columns (Microcon) and re-suspended in
MALDI matrix, rather than distilled water. Each sample
was applied to a MALDI target and left to dry thoroughly.
Of the 45 colonies that were prepared for MALDI mass
analysis, all revealed the presence of a mutation of some
type, as illustrated in Table 2. Forty-four (98%) of the muta-
tions were in the form of GC!AT transitions. Of these,
there was a 25:19 (56% : 42%) split in favour of the forward
ligated insert compared to reversed insert. The remaining
colony (2%) contained a large deletion, where part of the
insert had been removed. Figure 7 illustrates examples of
the possible mass spectra produced when deoxyoligonu-
cleotides are processed through E.coli. Figure 7A shows a
control insert, which originally contained a non-adducted
deoxyguanosine. The peak with m/z 3604 corresponds to
the unchanged top strand (TCCTCGCTCTTC), whilst the
peak with m/z 3834 is due to the complimentary bottom
strand (AAGAGCGAGGAA), which conﬁrms the correct
replication of the inserted deoxyoligonucleotide sequence.
All other control deoxyoligonucleotides resulted in the
appropriate unchanged masses after mass spectral analysis
(i.e. none were mutated). Figure 7B illustrates an example
of a mass spectrum from an insert that originally contained
an O
6-MedG, which was replicated in E.coli. The peak with
m/z 3588 corresponds to the top strand (TCCTCACTCTTC),
which now contains an adenine due to the induction of a
G!A transition as a result of the adduct, whilst the peak
with m/z 3849 is the bottom strand (AAGAGTGAGGAA)
containing a T instead of the original C, thus conﬁrming
the induction of a GC!AT transition mutation, as would
be predicted for an adduct of this type. A further eight
colonies were sequenced which had lost regions of the
supF gene, which resulted in a lack of PCR product and
one colony which had a mutation in the Bsrb1 restriction
site, which would have not allowed insertion of the INS1
deoxyoligonucleotide.
Detection of deoxyoligonucleotides transfected into
human Ad293 cells and recovered from E.coli using
mass spectrometry
Control and O
6-MedG containing deoxyoligonucleotide
inserts were transfected into Ad293 adenovirus-transformed
human kidney cells, where DNA repair, correct replication
or misincorporation of a mutant base could take place. The
processed plasmid was recovered after 48 h and used to trans-
form MBM7070 E.coli indicator bacteria. White colonies
were processed in the same way as described above prior to
DNA sequencing or mass spectral analysis. All samples were
analyzed in quadruplicate by MALDI-MS, with the resultant
spectra being combined for subsequent mass and mutation
classiﬁcation. Table 2 illustrates the mutation status of the
30 white colonies analyzed. All inserts resulted in mutations.
Twenty-eight (93%) of these were in the form of GC!AT
transitions. Of these transition mutations, 10 (33%) were in
the forward orientation and 18 (60%) had been ligated in
reverse. Two (7%) of the analyzed plasmid samples contained
deletions: where part of the deoxyoligonucleotide insert had
been removed. Figure 8 illustrates typical examples of the
mass spectra of deoxyoligonucleotides ampliﬁed and digested
from plasmid which was replicated in human Ad293 cells
then screened in MBM7070 E.coli. Figure 8A shows a deoxy-
oligonucleotide from a plasmid that originally had ligated
a control, non-adducted dG containing insert. The m/z
3604 peak corresponds to the non-mutant top strand
(TCCTCGCTCTTC), whilst the peak with m/z 3834 is the
Table 1. Monoisotopic masses of deoxyoligonucleotide standards
Oligo name Sequence Molecular weight Error
Observed Calculated p.p.m.
STANDARD1 TCCTCACTCTTC 3585.49 3585.58 25
STANDARD2 AAGAGTGAGGAA 3845.59 3845.67 19
STANDARD3 TCCTCGCTCTTC 3601.50 3601.57 20
STANDARD4 AAGAGCGAGGAA 3830.58 3830.67 23
STANDARD5 TCCTCCCTCTTC 3561.48 3561.57 25
STANDARD6 AAGAGGGAGGAA 3870.50 3870.67 44
STANDARD7 TCCTCTCTCTTC 3576.50 3576.57 19
STANDARD8 AAGAGAGAGGAA 3854.88 3854.68  52
Table 2. Table of mutations detected after processing in both human Ad293
cells and E.coli
Mutations induced in E.coli only (%)
G-A transitions
Total 44 98
Forward 25 56
Reversed 19 42
Deletions 1 2
Total mutations 45 100
Mutations induced in human Ad293 cells (%)
G-A transitions
Total 28 93
Forward 10 33
Reversed 18 60
Deletions 2 7
Total mutations 30 100
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therefore, conﬁrms the correct replication of the deoxy-
oligonucleotide insert in Ad293 cells, as previously observed
for E.coli above. Figure 8B is a mass spectrum of an insert
which originally contained an O
6-MedG. The peak with
m/z 3588 corresponds to the top strand (TCCTCACTCTTC),
which contains an adenine due to the induction of a G!A
transition, whilst the peak with m/z 3849 corresponds to
the complimentary bottom strand (AAGAGTGAGGAA),
containing a T rather than a C. This conﬁrms that in this
assay, when the O
6-MedG adduct is replicated in human
Ad293 cells it results in the incorporation of a deoxyadeno-
sine and the induction of a GC!AT transition, rather
than being repaired. A further 5 colonies lacked the PCR
priming regions and 6 had mutations in the Bsrb1 restric-
tion site, both detected by DNA sequencing, which resulted
in no PCR product or no digested deoxyoligonucleotide,
respectively.
DISCUSSION
The site-speciﬁc mutagenesis assay (SSMA-MS) described in
thispaperoffersconsiderablepotentialforfutureinvestigations
of deoxyoligonucleotides containing important DNA lesions
in human cells. These preliminary experiments have shown
that it is possible to insert a double stranded deoxyoligonu-
cleotide into the supF gene of the pSP189 shuttle vector
plasmid to knock out gene function. Recovered plasmids
which are screened in E.coli for the presence of inserts
can be picked and sequenced to determine whether a muta-
tion has been induced, the adduct has been bypassed with
incorporation of the correct base or repair has occurred. In
this developmental work the plasmids have been allowed
to replicate in bacteria only or in human Ad293 kidney
cells prior to being screened in bacteria. PCR using the
recovered plasmid as template, followed by digestion of
the PCR product using a restriction cocktail of Mbo11 and
Mnl1, results in the generation of small deoxyoligonu-
cleotides which have been characterized by MALDI-MS.
MALDI-MS provides an excellent platform for DNA anal-
ysis. It is more salt tolerant than ESI-MS, is very sensitive
and allows rapid analysis of an entire sample, rather than
requiring prior separation of components by HPLC. This
results in a more streamlined assay that beneﬁts from
reduced costs, both in terms of time and consumables, com-
pared to an ESI-MS method or DNA sequencing. These
assets make the method particularly amenable to high-
throughput analysis.
Figure 7. Examples of mass spectra for samples from E.coli only. (A) Control deoxyguanosine containing oligonucleotide. (B)O
6-MedG containing
oligonucleotide.
PAGE 9 OF 12 Nucleic Acids Research, 2006, Vol. 34, No. 22 e150Replication of the shuttle vector plasmid can be achieved
in a variety of human cell lines, making it possible to study
the effects of DNA adducts formed by a compound that is
implicated in a certain type of cancer in the most relevant
human cells. Furthermore, the adduct can be situated in a
key gene for the cancer in question. Since the SSMA-MS
method relies on chemical synthesis of the deoxyoligonu-
cleotide inserts, any DNA lesion can be studied as long as
it can be obtained in the form of phosphoramidites. Alterna-
tively, if this is not possible, deoxyoligonucleotide adducts
may be produced by direct reaction of the ultimate genotoxic
species with a synthetic deoxyoligonucleotide, although the
desired product will then need to be rigorously puriﬁed
prior to insertion into the plasmid.
Using a commercially available DNA adduct, O
6-MedG
and control non-adducted deoxyoligonucleotide inserts, we
have validated the method and obtained results which
compare to those observed with other mutagenesis systems.
O
6-MedG is a pre-mutagenic lesion in bacterial (32) and
mammalian cells (33), which predominantly results in
GC!AT transitions both in vitro and in vivo (34,35). The
presence of O
6-MedG adducts has been correlated with
increased organ speciﬁc tumourigenesis in rats induced by
DNA alkylating agents (36,37) and O
6-MedG has been
detected in both normal and tumour DNA isolated from
colorectal tissue of men and women undergoing surgery for
colorectal tumours (38). In vitro primer extension studies
show that the frequency of misincorporation of dNTPs oppo-
site or extension past, the O
6-MedG lesion varies with the
sequence context (39,40). Studies in bacterial cells using a
single site-speciﬁc adduct have shown that O
6-MedG is
able to miscode DNA, resulting in the incorporation of
the incorrect pyrimidine as its complimentary base when
replicated in E.coli (9,41) thus causing the characteristic
GC!AT transitions observed in the present study (42).
An excess of these mutations have also been detected in the
p53 tumour suppressor gene and ras oncogene in rodents
after treatment with methylating agents (43–45) and are
commonly seen in a variety of human tumour types (46,47).
The pSP189 plasmid used in this assay is double stranded,
therefore a uracil base was incorporated opposite the
O
6-MedG lesion in the INS1 deoxyoligonucleotide insert.
This should be removed by cellular uracil glycosylases
after transfection, encouraging translesion synthesis by
polymerases encountering the adduct rather than damage
avoidance and preferential replication of the non-adducted
strand. This increases the chances of a mutation occurring
and allows a more accurate study of the types of mutations
Figure 8. Examples of mass spectra for samples from human Ad293 cells, screened in E.coli.( A) Control deoxyguanosine containing oligonucleotide.
(B)O
6-MedG containing oligonucleotide.
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6-MedG adduct in human cells and bacterial
cells, whilst also validating the system. This approach has
been used to investigate O
6-substituted guanines (29,48) and
O
4-substituted thymines (48) replicated in E.coli and simi-
larly an increased mutagenicity was observed. A GC!AT
transition base substitution was observed whether the deoxy-
oligonucleotide containing plasmid was replicated in human
Ad293 cells or E.coli. In fact, no other base substitution
was seen and the only other mutations detected in this system
by adduct containing plasmid were manifested as a deletion
of part of the deoxyoligonucleotide insert directly after the
adduct position. This would suggest they arise as a conse-
quence of the O
6-MedG adducts, rather than the insertion
of a shortened synthetic deoxyoligonucleotide in the initial
stages of the assay prior to replication in human Ad293
cells or bacterial cells. In E.coli,O
6-alkylguanine can be
repaired by at least two alternative pathways: the base dam-
age is directly removed by transfer of the alkyl group to an
active cysteine residue on the inducible Ada or constitutive
Ogt methyltransferases (49–51) or by the nucleotide excision
repair (NER) pathway (52). Human cells have a single
analogous O
6-alkylguanine-DNA-alkyltransferase (MGMT)
(53) and a complex NER pathway (54,55). When DNA
adducts are repaired by NER a small region surrounding
the lesion is excised prior to the gap being ﬁlled by pold
and pole (55). Any reduction in the efﬁciency or accuracy
of this gap ﬁlling function can result in base deletions,
whereas the use of direct repair pathways (Ada, Ogt or
MGMT) should result in untraceable removal of the methyl
group only. The attempted repair of the lesions by NER
may therefore account for these observed deletions although,
at present, the activity of this pathway in these cells is
unknown. These results add further to the evidence that
O
6-alkyldG adducts are pro-mutagenic lesions and as such
are important in the mutagenicity and carcinogenicity of
alkylating agents which can form these lesions to varying
degrees.
We are continually developing improved methods for the
preparation of deoxyoligonucleotides prior to MS analysis,
such as the use of appropriate size exclusion or solid phase
columns, which will allow more efﬁcient salt removal and
greater puriﬁcation of the deoxyoligonucleotides of impor-
tance. We are also presently developing an MS/MS method,
which will allow us to further characterize deoxyoligonu-
cleotide inserts, such that from the collision induced dissocia-
tion products, it will be possible to determine the DNA
sequence and conﬁrm the precise position of the mutation
within the deoxyoligonucleotide.
In summary there are several beneﬁts of this new SSMA-
MS assay, both in terms of ease and speed in which deoxy-
oligonucleotides containing a DNA lesion can be inserted
and analyzed. There is no need for laborious construction
and puriﬁcation of a shuttle vector using scaffold deoxy-
oligonucleotides, since MS analysis provides high speciﬁcity
for vectors containing the adducted insert. The double
stranded pSP189 shuttle vector plasmid used contains origins
of replication for both bacterial and mammalian cells (19,20)
so comparisons can be made between cells differing in source
organ, species origin or repair proﬁciency. The increased
throughput and speed of MALDI-MS analysis allows the
comparison of either a set of DNA adducts in a ﬁxed
sequence context or a single DNA adduct with variable
sequence contexts, to be analyzed in a relatively short
time frame.
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